Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study

Mack Roach, Kathryn Winter, Jeffrey M. Michalski, James D. Cox, James A. Purdy, Walter Bosch, Xiao Lin, William S. Shipley

Research output: Contribution to journalArticlepeer-review

111 Scopus citations

Abstract

To assess the relationship between the dose to the bulb of the penis and the risk of impotence in men treated on Radiation Therapy Oncology Group (RTOG) 9406. Men enrolled on a Phase I/II dose-escalation study, RTOG 9406, who were reported to be potent at entry and evaluable (n = 158) were selected for inclusion. Follow-up evaluations were scheduled every 3, 4, and 6 months for the first, second, and the third through fifth years, then annually. At each follow-up visit an assessment of potency status was made. Penile structures were defined by a single observer blinded to the potency status, using Web-based, on-line software. The dosimetry for penile structures was calculated at the Quality Assurance Center at Washington University and provided to RTOG Statistical Headquarters to determine whether there was a relationship between dose and impotence. Patients whose median penile dose was ≥52.5 Gy had a greater risk of impotence compared with those receiving <52.5 Gy (p = 0.039). In a multivariate analysis neither age, the dose to the prostate, nor the use of hormonal therapy correlated with the risk of impotence. Dose to the bulb of the penis seems to be associated with the risk of radiation-induced impotence.

Original languageEnglish
Pages (from-to)1351-1356
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume60
Issue number5
DOIs
StatePublished - Dec 1 2004

Keywords

  • Impotence
  • Prostate cancer
  • Three-dimensional conformal radiotherapy

Fingerprint

Dive into the research topics of 'Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study'. Together they form a unique fingerprint.

Cite this